Life Science Start-Ups: Venture Funding, November 2013
This article was originally published in Start Up
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2013.
You may also be interested in...
During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.
During Q2 biopharmas brought in an aggregate $32.3bn in financings and device company fundraising totaled $9.5bn; while in vitro diagnostic firms and research tools players brought in $2bn across the period.
Genmab and AbbVie penned a broad oncology collaboration worth up to $3.9bn. Novo Nordisk entered into an agreement to acquire Corvidia Therapeutics for $725m up front in cash and up to $1.375bn in earn-outs.